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Introduction
In adults with rheumatoid arthritis several polymor-
phisms of C677T genotype (CT and TT) were associated
with increased toxicity and higher methotrexate (MTX)
efficacy. Homozygote CC polymorphism of A1298C gen-
otype was associated with toxicity.
Aim
To evaluate usefulness of MTHFR polymorphism and
folate concentration assessment for prediction of toxicity
and efficacy in children with juvenile idiopathic arthritis
(JIA). To test association between MTHFR polymorphism
and MTX polyglutamate concentration in erythrocytes
(EMTX).
Patients and methods
In 46 MTX treated children with JIA C677T and A1298C
polymorphisms of MTHFR, red cell folate (<800 nmol/l
vs. >800) and erythrocyte EMTX concentration were stud-
ied using previously described methods.
Results
The prevalence of CT and TT genotype was 37 and 13%,
distribution of AC and CC alleles 43 and 9%, respectively.
MTX toxicity was noticed in 41% of children (GI com-
plaints, raised transaminases, alopecia). 66% of patients
were classified as MTX responders. Folate concentration
was below 800 nmol/l in 28%. Presence of neither of
MTHFR polymorphisms correlated with side effects (p =
0, 71, χ2 test), clinical efficacy (p = 0, 18, χ2 test), quartiles
of EMTX (p = 0, 33) or folate concentration (p = 0, 71).
Conclusion
We have not found MTHFR polymorphism assessment
helpful as a biomarker for prediction of clinical efficacy or
toxicity in children with JIA. We have shown absence of
association of MTHFR genotype with efficacy of MTX ther-
apy.
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